Butty, Audrey; Gencer, Baris; Koskinas, Konstantinos C; Carballo, David; Räber, Lorenz; Klingenberg, Roland; Matter, Christian M; Lüscher, Thomas F; Windecker, Stephan; Muller, Olivier; Rodondi, Nicolas; Mach, François; Nanchen, David (2020). Control of cardiovascular risk factors and health behaviors in patients post acute coronary syndromes eligible for protein convertase subtilisin/kexin-9 inhibitors. International journal of cardiology, 299, pp. 289-295. Elsevier 10.1016/j.ijcard.2019.10.012
![[img]](https://boris.unibe.ch/style/images/fileicons/text.png) |
Text
Butty IntJCardiol 2020.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (342kB) |
|
|
Text
Butty IntJCardiol 2019_postprint.pdf - Accepted Version Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND). Download (189kB) | Preview |
BACKGROUND
We aimed to examine cardiovascular risk factors and health behaviors in patients with acute coronary syndromes (ACS) according to potential extension of eligibility criteria for protein convertase subtilisin/kexin-9 inhibitors (PCSK9i) to all patients with low-density lipoprotein cholesterol (LDL-c) equal or above 1.8 mmol/l.
METHODS
In this prospective cross-sectional study, patients with ACS between 2009 and 2016 and with available LDL-c at one year were considered. We defined three mutually exclusive groups of patients according to eligibility for PCSK9i: "not eligible", "currently eligible", and "newly eligible". We explored the control of cardiovascular risk factors and health behaviors.
RESULTS
Out of 3025 patients who had an ACS one year ago, 1071 (35.4%) were not eligible for PCSK9i, 415 (13.7%) were currently eligible, and 1539 (50.9%) were newly eligible. The proportion of patients with uncontrolled hypertension in the not eligible group was lower than in the group currently eligible (27.6% vs 33.6%, p = 0.02), but similar to the group newly eligible (27.6% vs 28.2%, p = 0.73). The proportion of smokers in the not eligible group was lower than in the group currently eligible (21.2% vs 28.0%, p = 0.02), but similar to the group newly eligible (21.2% vs 22.5%, p = 0.51).
CONCLUSIONS
More than half of patients with ACS would be additionally eligible for PCSK9i if prescription is extended from current guidelines to all patients with LDL-c equal or above 1.8 mmol/l. Patients currently eligible for PCSK9i one year after an ACS had a worst control of cardiovascular risk factors than patients potentially newly eligible.
Actions (login required)
 |
Edit item |